988 reports of this reaction
4.5% of all PIPERACILLIN AND TAZOBACTAM reports
#2 most reported adverse reaction
OFF LABEL USE is the #2 most commonly reported adverse reaction for PIPERACILLIN AND TAZOBACTAM, manufactured by Apotex Corp.. There are 988 FDA adverse event reports linking PIPERACILLIN AND TAZOBACTAM to OFF LABEL USE. This represents approximately 4.5% of all 21,987 adverse event reports for this drug.
Patients taking PIPERACILLIN AND TAZOBACTAM who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is moderately reported among PIPERACILLIN AND TAZOBACTAM users, representing a notable but not dominant share of adverse events.
In addition to off label use, the following adverse reactions have been reported for PIPERACILLIN AND TAZOBACTAM:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 988 FDA reports for PIPERACILLIN AND TAZOBACTAM. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 4.5% of all adverse event reports for PIPERACILLIN AND TAZOBACTAM, making it one of the most commonly reported side effect.
If you experience off label use while taking PIPERACILLIN AND TAZOBACTAM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.